



MINISTERIO
DE ECONOMÍA, INDUSTRIA
Y COMPETITIVIDAD

isc
Instituto
de Salud
Carlos III

Oportunidades en el Reto Social 1: "Salud, cambio demográfico y bienestar" 2018-2020 del programa Horizonte 2020

Girona, 07.02.2018

Juan E. Riese PhD MBA

Punto Nacional de Contacto – Reto Social 1 H2020 & IMI2

Experto Nacional en el Comité de Programa Reto Social 1

Oficina de Proyectos Europeos

*Subdirección General de Programas Internacionales
de Investigación y Relaciones Institucionales*

**dIB
Gi**

Institut
d'Investigació
Biomèdica
de Girona
Dr. Josep Trueta


Universitat de Girona

1.Introducción al HORIZON 2020

2.Programa de Trabajo 2018-2020 – Reto Social 1 “Salud, Cambio demográfico y Bienestar”

3.Otras oportunidades en Salud - Biomedicina



1.Introducción al HORIZON 2020

2.Programa de Trabajo 2018-2020 – Reto Social 1 “Salud, Cambio demográfico y Bienestar”

3.Otras oportunidades en Salud - Biomedicina



Objetivo H2020



Contribuir a la construcción de una economía basada en el conocimiento

- Más énfasis en el **impacto** de proyectos
- Fortaleciendo actividades **"bottom-up"**
- Mejorando el acceso a la **financiación** de las **empresas**
- Integrando **investigación** e **innovación**

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



MINISTERIO
DE ECONOMÍA, INDUSTRIA
Y COMPETITIVIDAD



Instituto
de Salud
Carlos III

H2020: Estructura

Ciencia excelente

Reforzar y ampliar la excelencia de la base científica de la Unión, así como a consolidar el Espacio Europeo de Investigación

Liderazgo industrial

Acelerar el desarrollo de las tecnologías e innovaciones que sustentarán las empresas del mañana

Retos sociales

Estimular la masa crítica de esfuerzos de investigación e innovación necesaria para alcanzar los objetivos políticos de la Unión

Tres pilares





H2020. Estructura

HORIZON 2020

€70.2 billion
(*budget is subject to change)

Excellent Science

European Research Council (ERC)

Marie Skłodowska-Curie Actions (MSCA)

Future Emerging Technology (FET)

European Research Infrastructure (ERI)

Industrial Leadership

Leadership in enabling and industrial technologies

Access to risk finance

Innovation in SMEs

Societal Challenges

Health, demographic change, and wellbeing

Food security, sustainable agriculture & forestry, marine & maritime research & inland water research

Secure, clean & efficient energy

Smart, green & integrated transport

Climate action, resource efficiency & raw materials

Inclusive, innovative & reflective societies

Secure Societies

Spreading excellence and widening participation

Science with and for society

European Institute of Innovation and Technology (EIT)

Non-nuclear direct actions of the Joint Research Centre (JRC)

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



Pilar 3 - Retos Sociales

III. Prioridad «Retos de la sociedad»		29.679
1. Salud, cambio demográfico y bienestar		7.472
2. Seguridad alimentaria, agricultura y silvicultura sostenibles, investigación marina, marítima y de aguas interiores y Bioeconomía		3.851
3. Energía segura, limpia y eficiente		5.931
4. Transporte inteligente, ecológico e integrado		6.339
5. Acción por el clima, medio ambiente, eficiencia de los recursos y materias primas		3.081
6. Europa en un mundo cambiante – Sociedades inclusivas, innovadoras y reflexivas		1.309
7. Sociedades seguras – Proteger la libertad y la seguridad de Europa y de sus ciudadanos		1.695

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



Hablaremos de

1.Introducción al HORIZON 2020

2.Programa de Trabajo 2018-2020 – Reto Social 1 “Salud, Cambio demográfico y Bienestar”

3.Otras oportunidades en Salud - Biomedicina

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



Reto Social 1 “Salud, Cambio Demográfico y Bienestar”



Better Health for all

- Envejecimiento de la población
- Ciudadanos mejor informados y mayores exigencias a los proveedores de atención médica por parte de los pacientes
- Solicitud de sistemas sanitarios más personalizados y sostenibles

Retos específicos:

Entender mejor la salud y la enfermedad
- la **medicina personalizada**

La carga de las **enfermedades crónicas e infecciosas**

Mejoras en el desarrollo de fármacos

El concepto de Medicina Personalizada según la CE



Personalised medicine



Personalised Medicine is defined as a medical model using characterization of individuals' phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention

(Horizon 2020 Societal Challenge 1 Advisory Group Report)

Hacia las convocatorias de SC1 2018-2019-2020

7 prioridades repartidas en 3 áreas

Area 1. Better health and care, economic growth and sustainable health systems (Topics BHC)

1. Personalised medicine
2. Innovative health and care industry
3. Infectious diseases and improving global health
4. Innovative health and care systems – Integration of care
5. Decoding the role of the environment for health and well-being

Area 2. Digital transformation in health and care (Topics DTH)

Area 3. Trusted digital solutions and cybersecurity in health and care (Topics TDS)

Otras acciones: premios (en conv. 2020); Instrumento PYME y FTI aparte



SCI-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities

Specific Challenge: The increasing number of individuals with co-and multimorbidities poses an urgent need to improve management of patients with multiple co-existing diseases. A better understanding of their causative mechanisms is needed to develop early diagnosis, efficient prevention and monitoring, and better treatments adapted to co- and multimorbid patients throughout their life course. Furthermore, there are many different etiological models of comorbid conditions (e.g., direct causation model or a consequence of treatment). In this context, capturing and measuring patient's complexity in the context of co- and multimorbidities is crucial for adequate management of these conditions and requires innovative approaches.

Scope: Proposals should identify and validate causative mechanisms (e.g. molecular, genetic, correlative, drug-drug interaction) combining mental and physical disorders through the integration of basic, pre-clinical and/or clinical research¹¹. Applicants should prove the relevance of the identified mechanisms for co-morbid development. Where pertinent, development of biomarkers and other technologies for diagnosis and monitoring of comorbid conditions in patients is encouraged. A purposeful exploitation of existing data, biobanks, registries and cohorts is expected¹², but does not exclude generation of new data. Sex and gender aspects, age, socio-economic, lifestyle and behavioural factors and any other non-health related individual attributes should be taken into consideration. SME participation is strongly encouraged.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

- New directions for clinical research to improve prevention, diagnosis, prognosis, therapy development, and management of co- and multimorbidities.
- Whenever relevant identified biomarkers for more accurate and earlier diagnosis, prognosis as well as monitoring of patients' condition.

Type of Action: Research and Innovation action

The conditions related to this topic are provided at the end of this call and in the General Annexes.

¹ Clinical trials are excluded

² Including any national, EU or international resource or infrastructure if appropriate.

Fuente:
Programa de
Trabajo
publicado el 7
de noviembre
de 2017



Call – Better Health and care, economic growth and sustainable health systems

1.1. Personalised Medicine (I)

- SC1-BHC-01-2019: Understanding causative mechanisms in co- and multimorbidities (4-6 M€/proyecto; 12-17 proyectos – total 70 M€)
- SC1-BHC-02-2019: Systems approaches for the discovery of combinatorial therapies for complex disorders (4-6 M€/proyecto; 8-12 proyectos – total 50 M€)
- SC1-BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease (10-15 M€/proyecto 3-5 Proyectos – total 50 M€)
- SC1-BHC-04-2018: Rare Disease European Joint Programme Co-Fund (50 M€/Proyecto; 1 Proyecto – total 50 M€)

1.1. Personalised Medicine (II)

- SC1-BHC-05-2018: International flagship collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches (4-6 M€/proyecto; 6-10 proyectos – total 40 M€)
- SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine (1,5-2M€; 3 proyectos – total 8 M€ - 1 proyecto/año)
- SC1-HCO-02-2018: Data integration and data-driven in-silico models for enabling personalised medicine - a European standardization framework (1,5-2 M€; 1 proyecto – total 2 M€)
- SC1-HCO-04-2018: ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND) (4-5 M€; 1 proyecto – total 5 M€)

1.2. Innovative health and care industry

- SC1-BHC-07-2019: Regenerative medicine: from new insights to new applications (6-8M€; 6-8 proyectos – total 50 M€)
- SC1-BHC-09-2018: Innovation platforms for advanced therapies of the future (12-15M€; 4-5 proyectos – total 50 M€)
- SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis (9-11 M€; 3-4 proyectos – total 40 M€)
- SC1-HCO-05-2018: Strengthening regulatory sciences and supporting regulatory scientific advice (1,5-2M€; 1 Proyecto – total 2 M€)

1.3 Infectious diseases and improving global health (I)

- SC1-BHC-13-2019: Mining big data for early detection of infectious disease threats driven by climate change and other factors (12-15 M€; 2-3 proyectos – total 30 M€)
- SC1-BHC-14-2019: Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases (6-10 M€; 10-16 proyectos – total 95 M€)
- SC1-BHC-15-2018: New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID) (5-10 M€; 5-10 proyectos – total 52 M€) (lump sum pilot)

1.3 Infectious diseases and improving global health (II)

- SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes (2-4 M€; 5-10 proyectos – total 20 M€)
- SC1-BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC) (2 - 4M€; 6-12 proyectos – total 25 M€)
- SC1-BHC-19-2019: Implementation research for maternal and child health (2-4M€; 6-12 proyectos – total 25 M€)

1.3 Infectious diseases and improving global health (III)

- SC1-BHC-21-2018: Research on HIV, tuberculosis and/or hepatitis C in patients with mono-, co-infections or comorbidities in the contest of fostering collaboration with the Russian Federation (2-4 M€; 2-5 proyectos – total 10 M€)
- SC1-HCO-06-2018: Establishment of an International Network of Research Centres to help address governance and other challenges in the preparedness for and the response to infectious threats (2-3 M€; 1 proyecto – total 3 M€)

1.3 Infectious diseases and improving global health (IV)

- SC1-HCO-08-2018: Creation of a European wide sustainable clinical research network for infectious diseases (2-3M€; 1 proyecto – total 3 M€)
- SC1-HCO-09-2018: Building international efforts on population and patient cohorts (1-2 M€; 1 proyecto – total 2 M€)
- SC1-HCO-10-2018: Coordinating European brain research and developing global initiatives (1-2 M€; 1 proyecto – total 2 M€)
- SC1-HCO-11-2018: Strategic collaboration in health research and innovation between EU and China (0,8-1 M€; 1 proyecto – total 1 M€)

1.4 Innovative health and care systems - Integration of care (I)

- SC1-BHC-22-2019: Mental health in the workplace (2-4 M€; 7-15 proyectos – total 30 M€)
- SC1-BHC-23-2018: Novel patient-centred approaches for survivorship, palliation and/or end-of-life care (3-4 M€; 11-14 proyectos – total 44 M€)
- SC1-BHC-25-2019: Demonstration pilots for implementation of personalised medicine in health care (18 - 20 M€; 3 proyectos – total 60 M€)
- SC1-BHC-26-2018: HTA research to support evidence-based healthcare (5-10 M€; 1-2 proyectos – total 10 M€)
- SC1-HCO-12-2018: Innovation in health care – a CSA towards using pre-commercial procurement and public procurement of innovative solutions in health care systems (1,5-2 M€; 1 proyecto – total 2 M€)

1.5 Decoding the role of the environment for health and well-being

- SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (4-6 M€; 8-12 proyectos – total 52 M€)
- SC1-BHC-28-2019: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health (8-12M€; 4-6 proyectos – total 50 M€)
- SC1-HCO-13-2018: Setting the priorities for a European environment, climate and health research agenda (2-3 M€; 1 proyecto – total 3 M€)

Call – Digital transformation in Health and Care (I)

- SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment (3-5 M€; 5-7 proyectos – total 35 M€)
- SC1-DTH-03-2018: Adaptive smart working and living environments supporting active and healthy ageing (3-4 M€; 6-8 proyectos – total 25 M€)
- SC1-DTH-05-2019: Large scale implementation of digital innovation for health and care in an ageing society (2-5 M€; 2-5 proyectos – total 10 M€)
- SC1-DTH-07-2018: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments (10-15 M€; 2-3 proyectos – total 35 M€)



Call – Digital transformation in Health and Care (II)

- SC1-DTH-08-2018: Prototyping a European interoperable Electronic Health Record (HER) exchange (6–10 M€; 3-5 proyectos – total 30 M€)
- SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products (5-8 M€; 2-4 proyectos – total 19 M€)
- SC1-DTH-10-2019-2020: Digital health and care services (5-6 M€; 3-4 proyectos – total 22 M€)
- SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care (4-6 M€; 3-5 proyectos – total 20 M€)
- SC1-HCC-01-2018: Supporting investment in smart living environments for ageing well through certification (1 M €; 1 proyecto – total 1 M€)

Call – Digital transformation in Health and Care (III)

- SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain (1,5 M€; 1 proyecto – total 1,5 M€)
- SC1-HCC-03-2018: Support to further development of international cooperation in digital transformation of health and care (2 M€; 1 proyecto – total 2 M€)
- SC1-HCC-04-2018: Digital health and care services – support for policy, strategy and (early) adoption (3 M€; 1 proyecto – total 3 M€)
- SC1-HCC-05-2018: Support to a Digital Health and Care Innovation initiative in the context of Digital Single Market strategy (4 M€; 1 proyecto – total 4 M€)

Call – Trusted Digital Solutions and Cybersecurity in Health and Care

- DT-TDS-01-2019: Smart and healthy living at home (15-20 M€; 3-4 proyectos – total 60 M€)
- SU-TDS-02-2018: Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures (3-5 M€; 7-12 proyectos – total 35 M€)
- SU-TDS-03-2018: Raising awareness and developing training schemes on cybersecurity in hospitals (1 M€; 1 proyecto – total 1 M€)



Tabla de fechas (I)

Conv.	Nº de topic	Apertura	Fecha de cierre
Convocatoria BHC			
2018	SC1-BHC-3 / 4 / 5 / 9 / 16 / 18 / 21 / 23 / 26 / 27		18.04.2018
	SC1-HCO-2 / 4 / 5 / 6 / 9 / 10 / 11 / 12 / 13	07.11.2017	
	SC1-BHC-15		Etapas Etapas 1 06.02.2018 Etapas 2 04.09.2018
2019	SC1-BHC-7 / 10 / 13 / 28 SC1-HCO-1 / 2	26.07.2018	16.04.2019
	SC1-BHC-1 / 2 / 14 / 19 / 22 - 25		Etapas Etapas 1 02/10/2018 Etapas 2 16.04.2019

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



Tabla de fechas (II)

Conv.	Nº de topic	Apertura	Fecha de cierre
Convocatoria DTH			
2018	SC1-DTH-3 / 7 / 8 / SC1-HCC-1 / 3 / 4 / 5	07.11.2017	24.04.2018
2019	SC1-DTH-1 / 5 / 9 / 11 SC1-HCC-2	16.10.2018	24.04.2019
2019	SC1-DTH-10	26.07.2018	14.11.2018

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



Tabla de fechas (III)

Conv.	Nº de topic	Apertura	Fecha de cierre
Convocatoria TDS			
2018	SC1-SU-TDS- 02/03	07.11.2017	24.04.2018
2019	DT-TDS-01	26.07.2018	14.11.2018

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020

Avance convocatorias 2020

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



MINISTERIO
DE ECONOMÍA, INDUSTRIA
Y COMPETITIVIDAD



Instituto
de Salud
Carlos III

Prioridad 1.1. Personalised Medicine

- SC1-BHC-06-2020: Digital diagnostics – developing tools for clinical decisions integrating in vitro and in vivo diagnostics
- SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine
- SC1-HCO-03-2020: Improving EU-13 participation in EU-supported health research programmes
- SC1-HCO-14-2020: ERA-NET Place holder 2



Priority 1.2 Innovative health and care industry

- SC1-BHC-08-2020: New therapies for Non Communicable Diseases
- SC1-BHC-11-2020: New, animal-free regulatory test methods for human safety testing at the horizon of 2030
- SC1-BHC-12-2020: Boosting the translation of results of health research into validated, innovative applications



Priority 1.3 Infectious diseases and improving global health

- SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) 2
- SC1-BHC-20-2020: Using pre-commercial procurements and public procurement of innovative solutions in health care systems to: - reduce the risk of hospital-acquired infections and/or - improve integrated care
- SC1-HCO-07-2020: ERA-NET Place holder 1

Priorities 1.4 and 1.5

Priority 1.4 Innovative health and care systems – Integration of care

- SC1-BHC-24-2020: Healthcare interventions for the management of the elderly multimorbid patient

Priority 1.5 Decoding the role of the environment for health and well-being

- SC1-BHC-29-2020: Environment, climate change and health – novel mitigating measures for improving population health

Call – Digital Transformation and Care

- SC1-DTH-02-2020: Personalised early risk prediction, prevention and intervention, RIA
- SC1-DTH-04-2020: International cooperation in digital solutions and robotics for independent living
- SC1-DTH-06-2020: Accelerating the uptake of *in-silico* methods for testing medicines with dermatological use



Call – Digital Transformation in Health and Care

- SC1-DTH-10-2019-2020: Digital Health and care services
- SC1-HCC-06-2020: Support to eHealth Innovation ecosystems in Europe
- SC1-HCC-07-2020: Support for European eHealth Interoperability roadmap deployment
- SC1-HCC-08-2020: Scaling up innovation for active and healthy ageing
- SC1-HCC-09-2020: Supporting deployment of eHealth in developing countries for better health outcomes



Call – Trusted digital solutions and Cybersecurity in Health and Care

DT-ICT-13-2020 The smart hospital of the future

DT-TDS-04-2020 Demonstrating the potential and benefits of a European Digital Health Infrastructure for Personalised Medicine

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



MINISTERIO
DE ECONOMÍA, INDUSTRIA
Y COMPETITIVIDAD



Instituto
de Salud
Carlos III

Presupuestos Totales *

- **Convocatoria SC1 2018:** 621,19 M€
- **Convocatoria SC1 2019:** 686,38 M€
- **Convocatoria SC1 2020:** 697,72 M€

*: pueden verse modificados



Hablaremos de

1.Introducción al HORIZON 2020

2.Programa de Trabajo 2018-2020 – Reto Social 1 “Salud, Cambio demográfico y Bienestar”

3.Otras oportunidades en Salud - Biomedicina



Financiación de proyectos en Salud en otros Pilares de H2020

- NMBP-21-2018: Custom-made biological scaffolds for specific tissue regeneration and repair
- NMBP-22-2018: Osteo-articular tissues regeneration
- DT-NMBP-23-2020: Next generation organ-on-chip (RIA)

- SFS-04-2019/2020 Integrated health approaches and alternatives towards pesticide use
 - A. [2019]: Integration of plant protection in a Global Health approach
 - B. [2020] Biocidal and plant protection products
- SFS-16-2018 Towards more healthy and sustainable food



La Iniciativa de Medicamentos Innovadores 2 (IMI 2)

<http://www.imi.europa.eu/>



innovative
medicines
initiative

Europe's partnership
for health



La Iniciativa de Medicamentos Innovadores (IMI). Base conceptual

“Deciphering the complexity of human diseases and finding safe, cost-effective solutions that help people live healthier lives requires **collaboration across scientific and medical communities throughout the health care ecosystem.**”

Indeed, we must acknowledge that **no single institution, company, university, country, or government has a monopoly on innovation.**”

Sci Transl Med 29 January 2014:
Vol. 6, Issue 221, p. 221ed2
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3008294

[< Prev](#) | [Table of Contents](#) | [Next >](#)


EDITORIAL

DRUG DISCOVERY

Turning the Titanic

Elias A. Zerhouni

Los riesgos del desarrollo farmacéutico



El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020

¿Por qué hace falta IMI 2?

Los desarrollos clínicos son

complejos

arriesgados

caros


largos

ineficientes

Porque:

- Los mecanismos biológicos de las enfermedades son complejos.
- El diseño de los ensayos clínicos tiene que adaptarse al conocimiento científico.
- La normativa regulatoria debe adaptarse a la evolución de la ciencia.

La Iniciativa de Medicamentos Innovadores 2



El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020






La 13ª convocatoria de IMI (I)

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the innovative medicines initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling

Fuente: <http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13>

Abierta la convocatoria (1ª etapa) hasta 28 de febrero 2018

La 13ª convocatoria de IMI (II)

- CONCEPTION – continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now 
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system 
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease 
- Federated and privacy-preserving machine learning in support of drug discovery 
- Pilot programme on a clinical compound bank for repurposing 

Fuente: <http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13>

Hacia la 14ª convocatoria de IMI

1. Targeted immune intervention for treatment of non-response and remission
2. Non-invasive clinical molecular imaging of immune cells
3. Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
4. Centre of excellence – remote decentralised clinical trials

Fuente: <http://www.imi.europa.eu/apply-funding/future-topics>

Pero hay más oportunidades en Salud...



El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020



MINISTERIO DE ECONOMÍA, INDUSTRIA Y COMPETITIVIDAD




Instituto de Salud Carlos III

Las oportunidades en el European Innovation Council (EIC)*

European Innovation Council: pilot 2018-2020

€ 2.7 billion to support +5,000 SMEs and innovators



<https://ec.europa.eu/research/eic/index.cfm?pg=fundin>

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020

SME Instrument

- Funding awarded via a continuously open call, 4 cut-off dates per year
 - Phase 1 > EUR 50,000 grant (feasibility)
 - Phase 2 > EUR 0.5 Mio. to 2.5 Mio. (market-ready)
 - Phase 3: business acceleration services, including coaching, for SMEs (SMEi, FET-Open, FTI grant holders)
 - Fully bottom-up: no predefined topics
 - Evaluation criteria stress potential for market-creating innovation
 - Forms (part B) shorter and business language
 - Phase 2:
 - Quality threshold raised to 13
 - Interview by jury in second step, evaluators with technology and financial/commercial background, published early 2018
 - **Specific for Health:**
 - TRL 6 or higher (so, after first clinical trials – but no eligibility criterion),
 - 70 % DCs + 25% Ics' grant (no preferential treatment for any sector)
 - € 2.5 m and 2 years are max, but more can be requested, duly justified

Budget in € millions		
2018	2019	2020
480	552	601

Fast-Track to Innovation (FTI)

Acceleration support for industry-driven consortia to deliver market-creating, breakthrough innovation

- Funding awarded via a continuously open call -- three cut-off dates per year
- Business acceleration services, including coaching, for SMEs

Novelties

- The evaluation criteria stress potential for market-creating innovation:

Impact

- ✓ Solutions that can create new markets or disrupt existing ones are key targets
- ✓ Boosting (rapid) scale-up and competitiveness of European businesses

Excellence

- ✓ Bring important progress to or revolutionise an industrial sector, business practice or societal issue
- ✓ The degree of risk: be bold
 - Business acceleration services (including coaching) for SMEs
 - New submission form underway

Budget in € millions		
2018	2019	2020
100	100	100

FET Open

- Laying foundations for radically new future technologies
- From knowledge to new breakthrough technology
- High-risk / high-impact interdisciplinary research with:
 - Radical vision
 - Breakthrough technological target
 - High ambitions

Features

- The evaluation criteria emphasise (even more) potential for science-to-technology breakthrough
- Business acceleration services (including coaching) for SMEs
- Higher budget, including for connecting consortia to markets, business, innovation and IP intelligence, the EIC community in view of accelerating the impact of the funding awarded

Budget in € millions (more than 98% of total budget is for RIAs)

2018	2019	2020
186	166	364



EIC Horizon Prizes

Contests for challenge-driven inducement prizes to be awarded to those best addressing the following challenges:

- ✓ Innovative Batteries for eVehicles: EUR 10 M
- ✓ Fuel from the Sun: Artificial Photosynthesis: EUR 5 M
- ✓ **Early Warning for Epidemics: EUR 5 M**
- ✓ Blockchain for Social Good: EUR 5 M
- ✓ Low-Cost Space Launch: EUR 10 M
- ✓ Affordable High-Tech for Humanitarian Aid: EUR 5 M (split-out in 1 M awards)

Resumen oportunidades en el European Innovation Council (EIC)*

El Reto Social 1 de H2020 en las convocatorias 2018-2019-2020

Instrument →	SME-Instrument		FTI	FET-Open	EIC Pilot
	Phase 1	Phase 2			
For whom	One or more eligible ¹ SMEs		From 3 to 5 eligible ¹ entities (mostly industrial ²)	At least 3 eligible ¹ entities (some sizes)	At least 3 eligible ¹ entities (some sizes)
Maximum funding ⁴	50,000 €	2.5 M€	3 M€	3 M€	Varies for each prize
Total budget 2018-20	164 M€	1425 M€	3 M€	3 M€ (RIAs) 3 M€ (CSAs)	40 M€
Focus	Exploring the feasibility of a business idea (~ 6 months)	Breakthrough innovations in market innovation	Market innovation	Radically new technologies	6 different topics (major societal issues)

Full bottom-up and introduction of interviews are the main new features of the evaluation under EIC Pilot

- (1) Applicants must be established in a country associated to Horizon 2020
- (2) This industry involves the allocation of at least 60% of the budget to industry participants in the consortium, or (b) the presence of at least 3 industry participants in a consortium of three or four partners, or of three industry participants in a consortium of four partners
- (3) A FET-Open consortium must include at least 3 participants from 3 different EU Member States or Associated Countries. In addition, a legal entity from anywhere in the world can also be included in the consortium.
- (4) ...



*: Fuente: Comisión Europea

Juan E. Riese
jriese@eu-isciii.es
Tel. 918222181

Información sobre convocatorias en: <http://eu-isciii.es>

